Candel Therapeutics, Inc. CADL Non Cash Lease Expense
Non Cash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept cadl:NonCashLeaseExpense.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s non cash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s non cash lease expense?
- Candel Therapeutics, Inc. (CADL) reported non cash lease expense of $92K in Q1 2026.
- How has Candel Therapeutics, Inc.'s non cash lease expense changed year-over-year?
- Candel Therapeutics, Inc.'s non cash lease expense increased by 24.3% year-over-year, from $74K to $92K.
- What is the long-term trend for Candel Therapeutics, Inc.'s non cash lease expense?
- Over 3 years (2022 to 2025), Candel Therapeutics, Inc.'s non cash lease expense has grown at a 15.4% compound annual growth rate (CAGR), from $209K to $321K.
- What does non cash lease expense mean?
- This represents the portion of lease expenses that does not involve an immediate cash outflow, typically related to the amortization of right-of-use assets. It is used to reconcile net income to operating cash flow by adjusting for accounting expenses that do not impact liquidity.